Clinical Trial Update: ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating intravesical ResQ133A, a recombinant Mycobacterium (rMBCG), for non-muscle invasive bladder cancer in patients eligible fo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• ResQ133A (recombinant Mycobacterium (rMBCG))

Snippet

Sponsor: ImmunityBio, Inc. | Conditions: NMIBC | Phase 1, Phase 2 | Status: RECRUITING